Startup Avelos Therapeutics Inc. raised $8 million in series A funding that will launch the company’s biomarker-driven cancer therapy pipeline using its synthetic lethality platform. Participating in the series A funding were SV Investment, UTC Investment, Quad Investment Management, Timepolio Asset Management, Mirae Asset Venture Investment and Mirae Asset Capital.
New and updated preclinical and clinical data presented by biopharma firms at the European Society for Medical Oncology Congress 2022, including: Adagene, Akeso, Alphamab Oncology, Astellas, Astrazeneca, Daiichi Sankyo, Eisai, I-Mab, Merck, Seagen, Starpharma, Transcenta.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Aston Sci., Astrazeneca, Jacobio, Moderna, Novavax, Veru, Yishengbio.
Pharmaxis Ltd. has found new funding to breathe life into a drug that looked like it might sit on the shelf for a while, but now appears to be a good candidate for tackling Parkinson’s and other neurodegenerative diseases.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Beactica, Cellorigin, Cellusion, Cellvera Global, Dong-A ST Co., Hangzhou Celregen, Hitgen, Intravacc, Qilu, Samsung Bioepis, Shanghai Fosun, Takeda, Tetra, Tikomed, Unison Medicines, Vernalis Research.
Melbourne-based Occurx Pty Ltd. announced a AU$16 million (US$11 million) series B round that will progress lead candidate OCX-063 to phase II trials in chronic kidney disease. The capital raise was jointly led by Brandon Biocatalyst and Uniseed and includes a AU$1.5 million grant from Australian biomedical incubator Cureator.
RSS
